Photosoft™ is a new generation photosensitiser derived from chlorophyll which is hypothesised to identify and selectively accumulate within solid cancerous tumour tissues. Photosoft™ is activated at multiple light sensitivity ranges across a broad spectrum, and therefore has potential to be targeted to both surface and deep seated tumours.
Invion has an agreement with The Cho Group to conduct clinical development of Photosoft™ globally, leveraging the Company’s expertise. The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset. Invion has also been granted exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment of cancers.